288 related articles for article (PubMed ID: 28905031)
21. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
[TBL] [Abstract][Full Text] [Related]
22. The impact of discontinuation of sacubitril-valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction.
Amin OA; Alaarag AF
Anatol J Cardiol; 2021 Mar; 25(3):163-169. PubMed ID: 33690130
[TBL] [Abstract][Full Text] [Related]
23. Congestive heart failure: what should be the initial therapy and why?
Chatterjee K
Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
[TBL] [Abstract][Full Text] [Related]
24. Expanded table: Some drugs for HFrEF.
Med Lett Drugs Ther; 2019 Apr; 61(1569):e57-e62. PubMed ID: 31169798
[No Abstract] [Full Text] [Related]
25. Treatment of systolic and diastolic heart failure in the elderly.
Aronow WS
J Am Med Dir Assoc; 2006 Jan; 7(1):29-36. PubMed ID: 16413432
[TBL] [Abstract][Full Text] [Related]
26. Comparison chart: Some drugs for HFrEF.
Med Lett Drugs Ther; 2021 Jun; 63(1626):e1-e14. PubMed ID: 34181629
[No Abstract] [Full Text] [Related]
27. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
28. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
29. American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice.
Ahmed A
J Am Geriatr Soc; 2003 Jan; 51(1):123-6. PubMed ID: 12534856
[TBL] [Abstract][Full Text] [Related]
30. [Pharmacological therapy of heart failure with reduced ejection fraction].
Wieser M; Rhyner D; Martinelli M; Suter T; Schnegg B; Bösch C; Wigger O; Dobner S; Hunziker L
Ther Umsch; 2018 Sep; 75(3):180-186. PubMed ID: 30145973
[TBL] [Abstract][Full Text] [Related]
31. Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure.
Aronow WS
Cardiol Rev; 2006; 14(3):108-24. PubMed ID: 16628020
[TBL] [Abstract][Full Text] [Related]
32. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
[TBL] [Abstract][Full Text] [Related]
33. Comparison table: Some drugs for HFrEF.
Med Lett Drugs Ther; 2021 Mar; 63(1619):e1-e13. PubMed ID: 33755656
[No Abstract] [Full Text] [Related]
34. Current treatment of heart failure with reduction of left ventricular ejection fraction.
Aronow WS
Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1619-1631. PubMed ID: 27673415
[TBL] [Abstract][Full Text] [Related]
35. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
[TBL] [Abstract][Full Text] [Related]
36. Impact of sacubitril/valsartan on echo parameters in heart failure patients with reduced ejection fraction a prospective evaluation.
Bayard G; Da Costa A; Pierrard R; Roméyer-Bouchard C; Guichard JB; Isaaz K
Int J Cardiol Heart Vasc; 2019 Dec; 25():100418. PubMed ID: 31517034
[TBL] [Abstract][Full Text] [Related]
37. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
Marques da Silva P; Aguiar C
Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
[TBL] [Abstract][Full Text] [Related]
38. Drugs for chronic heart failure.
Med Lett Drugs Ther; 2019 Apr; 61(1569):49-54. PubMed ID: 31169796
[No Abstract] [Full Text] [Related]
39. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
Sandhu AT; Kohsaka S; Turakhia MP; Lewis EF; Heidenreich PA
JAMA Cardiol; 2022 Feb; 7(2):130-139. PubMed ID: 34757380
[TBL] [Abstract][Full Text] [Related]
40. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
